Somerset NHS Foundation Trust, Sano Genetics and Predictive Health Intelligence have received £800k from the Innovate UK funding competition to develop and test a system that can identify high-risk liver disease cases.
All three aim to be able to detect cases much earlier than current methods, as well as rapidly progressing cases.
Typically, liver disease is detected late, but this new system could be a cost-effective solution for population-wide screening.
Cambridge-based company Sano Genetics, which accelerates precision medicine research, will work with Predictive Health Intelligence and Somerset NHS Foundation Trust to identify high-risk liver disease cases from common blood tests already in the NHS database. A new approach has been developed for
Additionally, the team will collaborate with Tawazun Health, experts in mobile, non-invasive liver scanning technology.
Tim Jobson, Medical Director of Predictive Health Intelligence, said: “The time has come to end late diagnosis of liver disease, which places a huge burden on the nation’s health and causes 26,000 premature deaths every year and 100,000 lives are lost every year.
“Combining precision medicine with proven technologies has the potential to pave the way for national screening and risk-stratification for liver and metabolic disease. It can’t come soon enough.”
About 30% of the adult population will have signs of fatty liver disease. Therefore a highly selective approach is needed to identify those who are at risk.
The team will combine longitudinal biomarker analysis, non-invasive liver scanning and non-invasive genetic testing to identify cases of liver disease. Patients identified as being at risk will be invited to have a scan and take a DNA test at home using a simple kit from Sano Genetics.
Patients will be offered standard follow-up treatment plans and consultations, who will also have access to Sano’s patient engagement platform.
Patrick Short, CEO and co-founder of Sano Genetics, said: “This pioneering program could forever change the way we diagnose and treat liver disease. By combining genomics, non-invasive liver scanning and machine-learning techniques that already exist, we can save lives as well as NHS costs.
As the project progresses, additional NHS trust partners will be added to the programme.
With liver disease now the second leading cause of death among 35-49 year olds, more companies are focusing on how to detect it early. In April this year, NuraLogix announced new capability to assess fatty liver disease risk with an artificial intelligence (AI) model that uses facial blood patterns to predict risk.











